Key result
Tailoring DAPT after PCI to individual ischemic and bleeding risks optimizes net clinical benefit.
Why the study?
Clinical translation of completed trials evaluating drug combinations and treatment durations is challenging due to heterogeneous therapeutic approaches, prompting a need to optimize net clinical benefit.
This review provides an updated overview of dual antiplatelet therapy optimization in patients undergoing percutaneous coronary interventions to maximize net clinical benefit.
Supports risk-stratified DAPT post-PCI; extends evidence synthesis but leaves optimal strategies open to prospective trials.
Dual antiplatelet therapy is one of the cornerstones of modern percutaneous coronary interventions. The development of new therapeutic agents has significantly reduced ischemic events at the risk of increased bleeding complications. Therefore, efforts are currently focused on optimizing therapeutic algorithms to obtain the greatest anti-thrombotic benefit associated with the lowest risk of bleeding, that is, the greater net clinical benefit. A significant number of trials evaluating different drug combinations or adjustments in treatment duration have been completed. However, clinical translation of these results is often difficult due to the heterogeneity of the therapeutic approaches. The aim of this manuscript is to provide an updated review of the literature regarding the use of dual antiplatelet therapy in patients undergoing coronary angioplasty and stenting.
No takes yet. Share an insight, caveat, or question.
Davanzo et al. (2020) conducted a review in Percutaneous coronary interventions. Dual antiplatelet therapy was evaluated. Dual antiplatelet therapy strategies after percutaneous coronary interventions should be tailored to individual patient ischemic and bleeding risk profiles to optimize net clinical benefit.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: